# Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZT003 Injection Following Single and Multiple Subcutaneous Administration in Healthy Volunteers/Overweight or Obese Volunteers

> **NCT07184502** · PHASE1 · RECRUITING · sponsor: **Beijing QL Biopharmaceutical Co.,Ltd** · enrollment: 76 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ZT003
- **DRUG:** ZT003
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07184502
- **Lead sponsor:** Beijing QL Biopharmaceutical Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-16
- **Primary completion:** 2026-06-06
- **Final completion:** 2026-10-10
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2026-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07184502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07184502, "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZT003 Injection Following Single and Multiple Subcutaneous Administration in Healthy Volunteers/Overweight or Obese Volunteers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07184502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*